水飞蓟宾治疗高甘油三酯血症的自身对照研究——附80例报告

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (1403 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To certify if the drug silybum could decrease the blood triglycerides level of hypertriglyceridemia patients, and how adverse reactions would be produced on their liver and renal function or elsewhere. Methods: A total of 80 cases of hypertriglyceridemia(TG≥2.50 mmol／L) with cardiac cerebral vascular disease,or hepatic disease from out-patient department or admitted patients, were given silybum 0.2 bid orally to 30 or／and 60 days.Their blood lipids, fast blood glucose,liver and renal function were checked before treatment and one／or two months after treatment. And what else adverse reactions happened after treatment, if any, were all recorded. Results: 1.The effect of decreasing blood TG.: Evident (blood TG decreased≥40％):27.3% in the patients rechecked after one month, and 51% after two months. Effective (blood TC decreased≥20％, but< 40％): 49.1％ in the patients one month after treatment, and 30.6％ after two months. Inefficacy (blood TC decreased<20％):23.6％ after one month and 18.4％ after two months respectively, with the total efficacy 76.4％ after one month and 81.6％ after two months. 2. There were a few decrease of the level of blood total cholesterol(TC) after treatment both after one or two months, but were not significant statistically(P>0.05), and there were evidently no significant difference of HDL-C or LDL-C between their after treatment and before treatment levels. 3. There were not any adverse influence to liver or renal function, and fasting blood glucose, whenever after taking the drug one or two months; on the contrary, the drug can improve or even treat the abnormal liver function such as to decrease the elevated blood transaminase prominently. 4.All patients hadn＇t any noxious adverse action to be recorded. Conclusion: Silybum can decrease the bood triglyceride level of hypertriglyceridemia patients, without any adverse influence to liver or kidney function, or other toxic action. And silybum can even improve or treat the abnormal liver function, to decrease abnormal elevated blood transaminase evidently, so that it could be suggested to be used as the first line drug to treat the hypertriglyceridemia.

Received: 25 December 2012

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2013/V23/I2/170

[1]中华医学会心血管病学分会循证医学评论专家组,中国老年学学会心脑血管病专业委员会. 甘油三酯增高的血脂异常防治中国专家共识［J］.中华心血管病杂志,2011,39(9):793-796.

［2］中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.血脂相关性心血管剩留风险控制的中国专家共识［J］.中华心血管病杂志,2012,40(7):547-551.

［3］Tirosh A， Rudich A, Shochat T,et al.Changes in triglyceride levels and risk for coronary heart disease in young men［J］.Ann Intern Med,2007,147(6):377-385.

［4］Miller M,Cannon CP,Murphy SA,et al.Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI22 trial［J］.J Am Coll Cardiol,2008,51(7):724-730.

［5］鲁晓岚,董蕾,张宽学,等. 水飞蓟宾胶囊治疗脂肪肝疗效观察［J］.实用肝脏病学杂志,2008,11(6):398-400

［6］Fruchart JC,Sacks FM,Hermans MP,et al.The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients［J］.Diab Vasc Dis Res,2008,5(4):319-335.

［7］Liu J, Wang W, Wang M, et al. Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15 year follow-up of the Chinese Multiprovincial Cohort Study［J］. Diabetes Res Clin Pract, 2012,96(2):217-224.

［8］孙东,胡仕琦,王宇明,水飞蓟药理作用及其在肝病中的临床应用［J］.中国全科医学,10(22):1891-1893.

［9］麦凯,仇士杰.水飞蓟素对大鼠高血脂症的影响［J］.中华心血管病杂志,1987,15(1):49-51.

［10］杨杏英.水飞蓟素治疗高脂血症的对照试验30例［J］.药物流行病学杂志,1995,4(4):199-201.

［11］陈红,章同华,尉挺.水飞蓟宾对培养心肌细胞缺氧缺糖的保护作用［J］.第二军医大学学报, 1990,11(2):147-149.

［12］林爱友,芮耀诚. 水飞蓟宾对猪脑基底动脉5-脂氧化酶活性的抑制作用［J］.中国药理学报,1989,10(5):414-417.

［13］Berglund L,Brunzell JD,Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline［J］.J Clin Endocrinol Metab,2012,97(9):2969-2989.